GlassScriptPhysician profile
Michele A Friday
NPI 1750359857
$6,470.47
in general payments reported to CMS, 2019-2025
31 companies · $819 in 2025
The $819 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $539 · 2021: $1,079 · 2022: $1,300 · 2023: $1,360 · 2024: $677 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,836 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.61 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,189.55 | 2019-2025 | |
| Pfizer INC. | $782.29 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $727.66 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $521.37 | 2019-2025 | Brilinta, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $464.53 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $455.30 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $431.46 | 2021-2025 | Watchman Access System, General - Therapies |
| Abbott Laboratories | $334.45 | 2020-2023 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.82 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $255.30 | 2025 | |
| Amgen INC. | $204.68 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $131.11 | 2019-2021 | |
| Daiichi Sankyo INC. | $75.93 | 2020-2023 | Injectafer |
| Acist Medical Systems, INC. | $57.93 | 2019-2022 | |
| Novo Nordisk INC | $56.35 | 2021-2025 | Wegovy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $53.62 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $52.81 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $48.28 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $37.93 | 2020-2021 | |
| Abiomed | $35.25 | 2024 | Impella |
| Medtronic Vascular, INC. | $35.23 | 2020 | |
| Medtronic, INC. | $34.81 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.81 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $33.34 | 2019 | |
| Janssen Biotech, INC. | $32.11 | 2024 | Tremfya |
| Inspire Medical Systems, INC. | $24.87 | 2025 | Inspire |
| Cvrx, INC. | $23.81 | 2024 | Barostim Neo System |
| Biotronik INC. | $20.61 | 2019 | |
| Lilly USA, LLC | $18.23 | 2025 | Mounjaro, Zepbound |
| Terumo Medical Corporation | $15.28 | 2022 | |
| Astellas Pharma US INC | $12.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Friday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.